Milan, Italy | Exom Group is proud to be part of the Geremy project – a project seeking a genetic cure for inherited arrhythmogenic cardiomyopathy (ACM), a rare cardiac disease – funded by the European Union as part of the Horizon 2022 program.
We are joining forces with several European research centers, uniting our expertise in clinical trials with the know how of leading experts in preclinical research and cardiac genetics.
Our involvement also brings decades of knowledge and experience in conducting clinical trials from a CRO perspective. In helping to find a cure for inherited arrhythmogenic cardiomyopathy (ACM) – a rare cardiac disease – we have the opportunity to make a real difference in the lives of those affected.
We look forward to playing our role in this ambitious effort, using our know-how and expertise to bring the project one step closer towards translational success. Working together, we hope to create positive outcomes and make a lasting impact on patient care.